JPH08208510A - インターフェロン組成物 - Google Patents

インターフェロン組成物

Info

Publication number
JPH08208510A
JPH08208510A JP7277375A JP27737595A JPH08208510A JP H08208510 A JPH08208510 A JP H08208510A JP 7277375 A JP7277375 A JP 7277375A JP 27737595 A JP27737595 A JP 27737595A JP H08208510 A JPH08208510 A JP H08208510A
Authority
JP
Japan
Prior art keywords
interferon
formulation
administration
formulations
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7277375A
Other languages
English (en)
Japanese (ja)
Inventor
Charanjit Rai Behl
チャランジット・ライ・ベール
Aruna Sudhir Railkar
アルナ・スドヒア・ライカー
Navnit Hargovindas Shah
ナブニット・ハルゴビンダス・シャー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JPH08208510A publication Critical patent/JPH08208510A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP7277375A 1994-11-03 1995-10-25 インターフェロン組成物 Pending JPH08208510A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33370294A 1994-11-03 1994-11-03
US08/333702 1994-11-03

Publications (1)

Publication Number Publication Date
JPH08208510A true JPH08208510A (ja) 1996-08-13

Family

ID=23303915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7277375A Pending JPH08208510A (ja) 1994-11-03 1995-10-25 インターフェロン組成物

Country Status (4)

Country Link
JP (1) JPH08208510A (en, 2012)
DE (1) DE19540669A1 (en, 2012)
FR (1) FR2726470B1 (en, 2012)
IT (1) IT1275802B1 (en, 2012)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010053135A (ja) * 2001-04-18 2010-03-11 Prometic Biosciences Inc 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
US9682054B2 (en) 2003-02-07 2017-06-20 Prometic Pharma Smt Limited Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
JP2002265383A (ja) * 2001-03-14 2002-09-18 Mitsubishi Pharma Corp インターフェロンα注射用液状製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
ZA898331B (en) * 1988-11-22 1990-07-25 Hoffmann La Roche Pharmaceutical compositions
DE3919982A1 (de) * 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh Orale lipidarzneiform
NL9101176A (nl) * 1991-07-05 1993-02-01 Stork Brabant Bv Zeefdrukinrichting met continue rapportering van roterende sjablonen.
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
JP3418423B2 (ja) * 1993-03-03 2003-06-23 久光製薬株式会社 経粘膜投与用薬剤組成物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010053135A (ja) * 2001-04-18 2010-03-11 Prometic Biosciences Inc 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
US7745488B2 (en) 2001-04-18 2010-06-29 Prometic Biosciences, Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US8487001B2 (en) 2001-04-18 2013-07-16 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US9682054B2 (en) 2003-02-07 2017-06-20 Prometic Pharma Smt Limited Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis

Also Published As

Publication number Publication date
IT1275802B1 (it) 1997-10-17
FR2726470B1 (fr) 1999-02-26
ITMI952202A1 (it) 1997-04-25
ITMI952202A0 (en, 2012) 1995-10-25
DE19540669A1 (de) 1996-05-09
FR2726470A1 (fr) 1996-05-10

Similar Documents

Publication Publication Date Title
US5719122A (en) Pharmaceutical compositions containing a calcitonin
JP3549542B2 (ja) 経口用ペプチド薬剤
JP5749255B2 (ja) Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
CN1229136C (zh) 供局部施用于眼组织的泪腺特异性乳状液
JP2003506476A (ja) 親水性治療剤の増強された吸収のための組成物および方法
ATE497384T1 (de) Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
EP0601053A1 (en) Compositions and methods for the sublingual or buccal administration of therapeutic agents
Seeff Drug-induced chronic liver disease, with emphasis on chronic active hepatitis
EP0177342A2 (en) Oral formulation of therapeutic proteins
Ruggieri et al. Ponesimod in the treatment of relapsing forms of multiple sclerosis: An update on the emerging clinical data
NL8701143A (nl) Farmaceutische preparaten.
Morioka et al. Vulvitis circumscripta plasmacellularis treated successfully with interferon alpha
JPH08208510A (ja) インターフェロン組成物
Lee et al. Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats
Pessayre et al. Chronic active hepatitis and giant multinucleated hepatocytes in adults treated with clometacin
Frulloni et al. Salivary gland involvement in patients with chronic pancreatitis
US20010012830A1 (en) Combination therapy method for treating chronic hepatitis B
Marcellin et al. Randomized controlled trial of adenine arabinoside 5′‐monophosphate in chronic active hepatitis B: comparison of the efficacy in heterosexual and homosexual patients
US5817624A (en) Permeation enhancer compositions for increased absorption of therapeutic proteins through the colonic membrane
US5011824A (en) Rectal motilin preparation
Lovero et al. A case of severe transaminase elevation following a single ustekinumab dose with remission after drug withdrawal
US6106868A (en) Method for the treatment of hepatitis
JPH08183741A (ja) 経粘膜投与用製剤
HUT69400A (en) Pharmaceutical compositions containing nonionic surfractants
US5389366A (en) Neocarzinostatin derivative composition for oral administration